Dependence on US FDA approvals for complex launches
Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.
high · management_commentary
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Revlimid revenue sustainability
Revenue from lenalidomide (Revlimid) is subject to confidential agreements and competitive pressures; management declined to provide specific guidance on future sales.
medium · analyst_questionCurrency risk in Russia
Russia business faces unfavorable forex movements; despite hedging, devaluation could impact reported revenues.
medium · management_commentaryImpairment risk from supply chain issues
A product faced procurement constraints from contract manufacturers, leading to a ₹92 crore impairment; similar issues could affect other products.
medium · data_observation